Neuboron Therapy System

Neuboron Therapy System is a China-based oncology company focused on boron neutron capture therapy (BNCT) and appears to be the global-market commercialization vehicle established by Neuboron Medtech. The company develops and commercializes the NeuPEX accelerator-based BNCT system and related treatment infrastructure, including treatment planning software, patient positioning, radiation monitoring, and boron-containing diagnostic and therapeutic agents. Public company materials describe Neuboron more broadly as a BNCT total-solution provider founded in 2014 in Nanjing, while third-party databases indicate Neuboron Therapy System itself was founded in 2017. Its lead therapeutic program is boronophenylalanine, also referred to as NBB-001 or BPA, which entered Phase 1 testing in China for recurrent head and neck cancer in 2024. The company operates at the intersection of medical devices, radiotherapy, and oncology drug development.